“We’ve had a circuit breaker for an old dogma of more than 20 years”: Changes to opioid agonist treatment services during COVID-19, the CHOICE study

ANNA CONWAY1,2, CARLA TRELOAR2, SIONE CRAWFORD2, LOUISA DEGENHARDT4, GREGORY J DORE1, MICHAEL FARRELL4, JASON GREBELY1, ALISON D MARSHALL1,2

1 The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia 2Centre for Social Research in Health, UNSW Sydney, Sydney, NSW, Australia 3Harm Reduction Victoria, VIC, Australia 4National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia

Presenter’s email: <a.conway@unsw.edu.au>

Introduction: The COVID-19 pandemic required opioid agonist treatment (OAT) services to adapt quickly to ensure continuity of care. This study aimed to explore how OAT services responded to COVID-19 in relation to state-mandated restrictions in Australia.

Method: Semi-structured interviews were completed between August and December 2020 via telephone and videocall with people receiving OAT and providers. Prior to data collection, the interview guide was reviewed by a community reference panel comprised of people who use drugs to provide feedback on terminology and content. The analysis considers how the OAT service response to COVID-19 impacted the risks of: COVID-19 transmission, treatment non-adherence and adverse events related to increased access to unsupervised OAT.

Key Findings: 40 people receiving OAT (22 women, mean age=49, mean years receiving OAT=10, 31 recently injected drugs) and 30 OAT providers (10 women, 18 doctors, 9 nurses, 3 managers, mean years as OAT provider=11, 26 working in the public sector) were interviewed. Clinics broadly implemented three strategies to ensure continuity of care during COVID-19: 1) increasing access to unsupervised OAT dosing i.e., takeaways; 2) transitioning to telehealth appointments; and 3) redirecting people to community pharmacies for dosing. Potential risks produced by these service changes were largely mitigated by the provision of patient-centred care.

Discussion: Increased OAT flexibility during COVID-19 had the unintended consequence of moving some services towards a more person-centred model of care. Results reinforce the need to centre or indeed, include the voices of people receiving OAT in appraisals of this period to ensure optimal care.

Disclosure of Interest Statement: LD has received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma and Seqirus. GJD is a consultant/advisor and has received research grants from Merck, Gilead, and AbbVie outside the submitted work. JG is a consultant/advisor and has received research grants from AbbVie, Cepheid, Gilead, and Merck outside the submitted work. CT has received speaker fees from Abbvie and Gilead and has received a research grant from Merck outside the submitted work. All other authors declare no conflict of interest.